Literature DB >> 3046381

Lack of efficacy of carbamazepine in the treatment of panic disorder.

T W Uhde1, M B Stein, R M Post.   

Abstract

The authors conducted a controlled study of carbamazepine in the treatment of 14 patients with panic disorder. Although there was a statistically significant reduction in symptoms of anxiety on several measures, only one of the patients was judged to have a marked and sustained clinical improvement while taking carbamazepine. Forty percent of the patients had a decrease in frequency of panic attacks during carbamazepine treatment, 50% had an increase, and 10% showed no change. The presence of either EEG abnormalities or prominent psychosensory symptoms did not predict response to carbamazepine. These findings are discussed within the context of an epileptiform model for panic disorder.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3046381     DOI: 10.1176/ajp.145.9.1104

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  13 in total

Review 1.  Anticonvulsants in anxiety disorders.

Authors:  Gustavo Kinrys; Lisa E Wygant
Journal:  Curr Psychiatry Rep       Date:  2005-08       Impact factor: 5.285

2.  Psychotropic effects of antiepileptic drugs.

Authors:  Siddhartha Nadkarni; Orrin Devinsky
Journal:  Epilepsy Curr       Date:  2005 Sep-Oct       Impact factor: 7.500

3.  Treatment of benzodiazepine withdrawal symptoms with carbamazepine.

Authors:  D Garcia-Borreguero; T Bronisch; S Apelt; A Yassouridis; H M Emrich
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1991       Impact factor: 5.270

4.  Management of treatment-resistant panic disorder.

Authors:  Richard L Holt; R Bruce Lydiard
Journal:  Psychiatry (Edgmont)       Date:  2007-10

Review 5.  Antiepileptic drugs in the treatment of anxiety disorders: role in therapy.

Authors:  Michael Van Ameringen; Catherine Mancini; Beth Pipe; Mark Bennett
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 6.  [Anticonvulsants in the treatment of anxiety--an alternative treatment option?].

Authors:  P Zwanzger; D Eser; R Rupprecht
Journal:  Nervenarzt       Date:  2007-11       Impact factor: 1.214

Review 7.  Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders.

Authors:  Martin A Katzman; Pierre Bleau; Pierre Blier; Pratap Chokka; Kevin Kjernisted; Michael Van Ameringen; Martin M Antony; Stéphane Bouchard; Alain Brunet; Martine Flament; Sophie Grigoriadis; Sandra Mendlowitz; Kieron O'Connor; Kiran Rabheru; Peggy M A Richter; Melisa Robichaud; John R Walker
Journal:  BMC Psychiatry       Date:  2014-07-02       Impact factor: 3.630

8.  Anxiolytic effect of carbamazepine in the elevated plus-maze: possible role of adenosine.

Authors:  H Zangrossi; J R Leite; F G Graeff
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

Review 9.  Panic disorder. Pathophysiology and drug treatment.

Authors:  M R Johnson; R B Lydiard; J C Ballenger
Journal:  Drugs       Date:  1995-03       Impact factor: 9.546

Review 10.  The effectiveness of anticonvulsants in psychiatric disorders.

Authors:  Heinz C R Grunze
Journal:  Dialogues Clin Neurosci       Date:  2008       Impact factor: 5.986

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.